Citations

Citations to this article as recorded by  

• The role of adherence in patients with chronic diseases
  Michel Burnier
  European Journal of Internal Medicine.2024; 119: 1.     CrossRef
• Genetic insights into repurposing statins for hyperthyroidism prevention: a drug-target Mendelian randomization study
  Anqi Huang, Xinyi Wu, Jiaqi Lin, Chiju Wei, Wencan Xu
  Frontiers in Endocrinology.2024;[Epub]     CrossRef
• Targeting host-specific metabolic pathways—opportunities and challenges for anti-infective therapy
  Monika I. Konaklieva, Balbina J. Plotkin
  Frontiers in Molecular Biosciences.2024;[Epub]     CrossRef
• Neutrophil Extracellular Traps (NETs) and Atherosclerosis: Does Hypolipidemic Treatment Have an Effect?
  Petros Adamidis, Despoina Pantazi, Iraklis Moschonas, Evangelos Liberopoulos, Alexandros Tselepis
  Journal of Cardiovascular Development and Disease.2024; 11(3): 72.     CrossRef
• Modulating effects of crocin on lipids and lipoproteins: Mechanisms and potential benefits
  Habib Yaribeygi, Mina Maleki, Farin Rashid-Farrokhi, Payman Raise Abdullahi, Mohammad Amin Hemmati, Tannaz Jamialahmadi, Amirhossein Sahebkar
  Heliyon.2024; 10(7): e28837.     CrossRef
• Assessing the Benefits of Lifestyle Influences on Cardiovascu-lar Health After Acute Coronary Syndrome
  Marius Rus, Claudia Elena Stanis, Paula Marian, Lilliana Oana Pobirci, Loredana Ioana Banszki, Veronica Huplea, Gheorghe Adrian Osiceanu, Bianca-Maria Pop, Gabriela Dogaru, Felicia Liana Andronie-Cioara
  Balneo and PRM Research Journal.2024; 15(Vol.15, no): 660.     CrossRef
• ​Comprehensive mendelian randomization analysis of plasma proteomics to identify new therapeutic targets for the treatment of coronary heart disease and myocardial infarction
  Ziyi Sun, Zhangjun Yun, Jianguo Lin, Xiaoning Sun, Qingqing Wang, Jinlong Duan, Cheng Li, Xiaoxiao Zhang, Siyu Xu, Zeqi Wang, Xingjiang Xiong, Kuiwu Yao
  Journal of Translational Medicine.2024;[Epub]     CrossRef
• Hypercholesterolemia: A literature review on management using tafolecimab – a novel member of PCSK9 monoclonal antibodies
  Zaheer Qureshi, Mikail Khanzada, Adnan Safi, Eeshal Fatima, Faryal Altaf, Timothy J. Vittorio
  Annals of Medicine & Surgery.2024;[Epub]     CrossRef
• Therapeutic approach in the treatment of dyslipidemia: Novelties and challenges
  Katarina Lalić, Nataša Rajković, Ljiljana Popović, Sandra Singh-Lukač, Iva Rasulić, Ana Petakov, Milica Krstić, Marija Mitrović
  Galenika Medical Journal.2024; 3(9): 31.     CrossRef
• Lipid Variability Induces Endothelial Dysfunction by Increasing Inflammation and Oxidative Stress
  Marie Rhee, Joonyub Lee, Eun Young Lee, Kun-Ho Yoon, Seung-Hwan Lee
  Endocrinology and Metabolism.2024; 39(3): 511.     CrossRef
• Exploring the Perceptions and Behaviours of UK Prescribers Concerning Novel Lipid-Lowering Agent Prescriptions: A Qualitative Study
  Sarah Baig, Shahrauz Mughal, Yousuf Murad, Mandeep Virdee, Zahraa Jalal
  Pharmacy.2024; 12(4): 104.     CrossRef
• Need of education and training of healthcare professionals on the PCSK9 inhibitors in cardiovascular disease
  Jan Schjøtt, Kristine Heitmann
  European Journal of Cardiovascular Nursing.2024;[Epub]     CrossRef
• CXCL9, IL2RB, and SPP1, potential diagnostic biomarkers in the co-morbidity pattern of atherosclerosis and non-alcoholic steatohepatitis
  Xize Wu, Changbin Yuan, Jiaxiang Pan, Yi Zhou, Xue Pan, Jian Kang, Lihong Ren, Lihong Gong, Yue Li
  Scientific Reports.2024;[Epub]     CrossRef
• Lessons from PROMINENT and prospects for pemafibrate
  Jean-Charles Fruchart, Jamila Fruchart-Najib, Shizuya Yamashita, Peter Libby, Koutaro Yokote, Tatsuhiko Kodama, Yohei Tomita, Paul M. Ridker, Michel P. Hermans, Alberto Zambon
  Cardiovascular Diabetology.2024;[Epub]     CrossRef
• A novel lncRNA GM47544 modulates triglyceride metabolism by inducing ubiquitination-dependent protein degradation of APOC3
  Qianqian Xiao, Luyun Wang, Jing Wang, Man Wang, Dao Wen Wang, Hu Ding
  Molecular Metabolism.2024; 88: 102011.     CrossRef
• Advances in pharmacotherapy of dyslipidemia
  Harshitha Chinta
  National Journal of Pharmacology and Therapeutics.2024; 2(2): 68.     CrossRef
• ANGPTL3 as a target for treating lipid disorders in type 2 diabetes patients
  Jingfei Chen, Qin Luo, Yanfeng Yi, Jiangang Wang, Pengfei Chen, Fei Luo, Zhenfei Fang
  Lipids in Health and Disease.2024;[Epub]     CrossRef
• Assessing the effects of HMGCR, LPL, and PCSK9 inhibition on sleep apnea: Mendelian randomization analysis of drug targets
  Wei Tan, Xiujuan Deng, Xiaoning Tan, Guangbo Tan
  Medicine.2024; 103(43): e40194.     CrossRef
• Causal association between remnant cholesterol level and risk of cardiovascular diseases: a bidirectional two sample mendelian randomization study
  Lei Zhong, Bo Xie, Hai-Li Wang, Xiao-Wei Ji
  Scientific Reports.2024;[Epub]     CrossRef
• A bibliometric analysis of immunotherapy for atherosclerosis: trends and hotspots prediction
  Jing-Hui Wang, Guan-Rui Pan, Long Jiang
  Frontiers in Immunology.2024;[Epub]     CrossRef
• Liver cancer cells as the model for developing liver-targeted RNAi therapeutics
  Beibei Hou, Linhui Qin, Linfeng Huang
  Biochemical and Biophysical Research Communications.2023; 644: 85.     CrossRef
• Insights into Causal Cardiovascular Risk Factors from Mendelian Randomization
  C. M. Schooling, J. V. Zhao
  Current Cardiology Reports.2023; 25(2): 67.     CrossRef
• Secoisolariciresinol diglucoside and anethole ameliorate lipid abnormalities, oxidative injury, hypercholesterolemia, heart, and liver conditions
  Sana Noreen, Habib‐ur Rehman, Tabussam Tufail, Huma Badar Ul Ain, Chinaza Godswill Awuchi
  Food Science & Nutrition.2023; 11(6): 2620.     CrossRef
• Colesterol remanente, riesgo vascular y prevención de la arteriosclerosis
  Xavier Pintó, Marta Fanlo, Virginia Esteve, Jesús Millán, Agustín Blanco, Mariano Blasco, José Luís Díaz Díaz, Ángel Díaz Rodríguez, Alipio Mangas, Vicente Pascual, Juan Pedro Botet, Pablo Pérez Martínez
  Clínica e Investigación en Arteriosclerosis.2023; 35(4): 206.     CrossRef
• Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum
  Michael J. Wilkinson, Norman E. Lepor, Erin D. Michos
  Journal of the American Heart Association.2023;[Epub]     CrossRef
• The cell origins of foam cell and lipid metabolism regulated by mechanical stress in atherosclerosis
  Zhi Ouyang, Jian Zhong, Junyi Shen, Ye Zeng
  Frontiers in Physiology.2023;[Epub]     CrossRef
• Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux
  Alejandro Gugliucci
  Journal of Clinical Medicine.2023; 12(13): 4399.     CrossRef
• Remnant cholesterol, vascular risk, and prevention of atherosclerosis
  Xavier Pintó, Marta Fanlo, Virginia Esteve, Jesús Millán
  Clínica e Investigación en Arteriosclerosis (English Edition).2023; 35(4): 206.     CrossRef
• Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications
  Marios Spanakis, Danny Alon-Ellenbogen, Petros Ioannou, Nikolaos Spernovasilis
  Pharmacy.2023; 11(4): 130.     CrossRef
• Advances in Treatment of Dyslipidemia
  Jill Dybiec, Wiktoria Baran, Bartłomiej Dąbek, Piotr Fularski, Ewelina Młynarska, Ewa Radzioch, Jacek Rysz, Beata Franczyk
  International Journal of Molecular Sciences.2023; 24(17): 13288.     CrossRef
• Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease
  Elena Valeria Fuior, Evangelia Zvintzou, Theodosios Filippatos, Katerina Giannatou, Victoria Mparnia, Maya Simionescu, Anca Violeta Gafencu, Kyriakos E. Kypreos
  Biomedicines.2023; 11(10): 2696.     CrossRef
• Preparation, characterization and in vivo pharmacokinetic study of ginsenoside Rb1-PLGA nanoparticles
  Lixin Du, Huiling Lu, Yifei Xiao, Zhihua Guo, Ya Li
  Scientific Reports.2023;[Epub]     CrossRef
• Dysregulation of Cholesterol Homeostasis in Ovarian Cancer
  Zahraa Qusairy, Anne Gangloff, Shuk On Annie Leung
  Current Oncology.2023; 30(9): 8386.     CrossRef
• Riesgo residual. Conclusiones
  Ángel Cequier, José Luis Zamorano
  Revista Española de Cardiología Suplementos.2023; 23: 25.     CrossRef
• Causal effects of circulating lipids and lipid-lowering drugs on the risk of urinary stones: a Mendelian randomization study
  Zilong Tan, Jing Hong, Aochuan Sun, Mengdi Ding, Jianwu Shen
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• Bibliometric analysis of residual cardiovascular risk: trends and frontiers
  Lin Wang, Sutong Wang, Chaoyuan Song, Yiding Yu, Yuehua Jiang, Yongcheng Wang, Xiao Li
  Journal of Health, Population and Nutrition.2023;[Epub]     CrossRef
• Bempedoic acid: new evidence and recommendations on use
  Kristina Paponja, Ivan Pećin, Željko Reiner, Maciej Banach
  Current Opinion in Lipidology.2023;[Epub]     CrossRef
• Current Understanding on the Genetic Basis of Key Metabolic Disorders: A Review
  Kenneth Francis Rodrigues, Wilson Thau Lym Yong, Md. Safiul Alam Bhuiyan, Shafiquzzaman Siddiquee, Muhammad Dawood Shah, Balu Alagar Venmathi Maran
  Biology.2022; 11(9): 1308.     CrossRef
• Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
  Joon Ho Moon, Kyuho Kim, Sung Hee Choi
  Endocrinology and Metabolism.2022; 37(4): 575.     CrossRef

Statins have been shown to be very effective and safe in numerous randomized clinical trials, and became the implacable first-line treatment against atherogenic dyslipidemia. However, even with optimal statin treatment, 60% to 80% of residual cardiovascular risk still exists. The patients with familial hypercholesterolemia which results in extremely high level of low density lipoprotein cholesterol (LDL-C) level and the patients who are intolerant or unresponsive to statins are the other hurdles of statin treatment. Recently, new classes of lipid-lowering drugs have been developed and some of them are available for the clinical practice. The pro-protein convertase subtilisin/kexintype 9 (PCSK9) inhibitor increases the expression of low density lipoprotein (LDL) receptor in hepatocytes by enhancing LDL receptor recycling. The microsomal triglyceride transport protein (MTP) inhibitor and antisense oligonucleotide against apolipoprotein B (ApoB) reduce the ApoB containing lipoprotein by blocking the hepatic very low density lipoprotein synthesis pathway. The apolipoprotein A1 (ApoA1) mimetics pursuing the beneficial effect of high density lipoprotein cholesterol and can reverse the course of atherosclerosis. ApoA1 mimetics had many controversial clinical data and need more validation in humans. The PCSK9 inhibitor recently showed promising results of significant LDL-C lowering in familial hypercholesterolemia (FH) patients from the long-term phase III trials. The MTP inhibitor and antisesnse oligonucleotide against ApoB were approved for the treatment of homozygous FH but still needs more consolidated evidences about hepatic safety such as hepatosteatosis. We would discuss the benefits and concerns of these new lipid-lowering drugs anticipating additional benefits beyond statin treatment.

Citations

Citations to this article as recorded by  

• Role of PCSK9 inhibitors in the management of dyslipidaemia
  Tiny Nair
  Indian Heart Journal.2024; 76: S44.     CrossRef
• Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?
  Henriette Thau, Sebastian Neuber, Maximilian Y. Emmert, Timo Z. Nazari-Shafti
  Cardiology and Therapy.2024; 13(1): 39.     CrossRef
• UHPLC Specific Method for Simultaneous Determination of Probable Impurities of Ezetimibeand Simvastatin in Combined Dosage Form
  Anantha Lakshmi Vadivelu, Sathapathy Panduranga Vittal, Duvvuri Suryakala
  Oriental Journal Of Chemistry.2024; 40(1): 228.     CrossRef
• PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes
  Daniela Grejtakova, Iveta Boronova, Jarmila Bernasovska, Stefano Bellosta
  Cardiovascular Drugs and Therapy.2024;[Epub]     CrossRef
• LC‐MS based metabolite profiling, in‐vitro antioxidant and in‐vivo antihyperlipidemic activity ofNigella sativaextract
  Amit Kumar Shrivastava, Laxmi Shrestha, Buddhi Raj Pokhrel, Bishal Joshi, Gopal Lamichhane, Bojana Vidović, Niranjan Koirala
  eFood.2023;[Epub]     CrossRef
• Development of New Genome Editing Tools for the Treatment of Hyperlipidemia
  Giulio Preta
  Cells.2023; 12(20): 2466.     CrossRef
• High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine
  E. Reijnders, A. van der Laarse, J. W. Jukema, C. M. Cobbaert
  Frontiers in Cardiovascular Medicine.2023;[Epub]     CrossRef
• Riesgo residual. Conclusiones
  Ángel Cequier, José Luis Zamorano
  Revista Española de Cardiología Suplementos.2023; 23: 25.     CrossRef
• Anti-hyperglycemic, anti-hyperlipidemic, and anti-inflammatory effect of the drug Guggulutiktaka ghrita on high-fat diet-induced obese rats
  Samreen M. Sheik, Pugazhandhi Bakthavatchalam, Revathi P. Shenoy, Basavaraj S. Hadapad, Deepak Nayak M, Monalisa Biswas, Varashree Bolar Suryakanth
  Journal of Ayurveda and Integrative Medicine.2022; 13(3): 100583.     CrossRef
• New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
  Kyuho Kim, Henry N. Ginsberg, Sung Hee Choi
  Diabetes & Metabolism Journal.2022; 46(4): 517.     CrossRef
• A New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy
  Kyuho Kim, Sung Hee Choi
  Journal of Lipid and Atherosclerosis.2022; 11(3): 250.     CrossRef
• Tyramine exerts hypolipidemic and anti-obesity effects in vivo
  Thamires Maria Fontenele Morais, Tiago Sousa Melo, Mariana Brito Dantas, Jamile Magalhães Ferreira, Daniel Freire de Sousa, Emanuel Paula Magalhães, Ramon Róseo Paula Pessoa Bezerra de Menezes, Otília Deusdênia Loiola Pessoa, Mariana Lima Feitosa, Francis
  Brazilian Journal of Pharmaceutical Sciences.2022;[Epub]     CrossRef
• Statin adherence and risk of all-cause, cancer, and cardiovascular mortality among dyslipidemia patients: A time-dependent analysis
  Young Ran Lee, Sarah Soyeon Oh, Sung-In Jang, Eun-Cheol Park
  Nutrition, Metabolism and Cardiovascular Diseases.2020; 30(12): 2207.     CrossRef
• Efficient reabsorption of transintestinally excreted cholesterol is a strong determinant for cholesterol disposal in mice
  Ivo P. van de Peppel, Anna Bertolini, Theo H. van Dijk, Albert K. Groen, Johan W. Jonker, Henkjan J. Verkade
  Journal of Lipid Research.2019; 60(9): 1562.     CrossRef
• Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
  Jah Yeon Choi, Jin Oh Na
  Journal of Lipid and Atherosclerosis.2019; 8(2): 183.     CrossRef
• Effects of silymarin supplementation on blood lipids: A systematic review and meta‐analysis of clinical trials
  Hamed Mohammadi, Amir Hadi, Arman Arab, Sajjad Moradi, Mohammad Hossein Rouhani
  Phytotherapy Research.2019; 33(4): 871.     CrossRef
• Change in ALT levels after administration of HMG‐CoA reductase inhibitors to subjects with pretreatment levels three times the upper normal limit in clinical practice
  Hyunah Kim, Hyeseon Lee, Tong Min Kim, So Jung Yang, Seo Yeon Baik, Seung‐Hwan Lee, Jae‐Hyoung Cho, Hyunyong Lee, Hyeon Woo Yim, In Young Choi, Kun‐Ho Yoon, Hun‐Sung Kim
  Cardiovascular Therapeutics.2018;[Epub]     CrossRef
• Host-targeting therapies for hepatitis C virus infection: current developments and future applications
  Emilie Crouchet, Florian Wrensch, Catherine Schuster, Mirjam B. Zeisel, Thomas F. Baumert
  Therapeutic Advances in Gastroenterology.2018;[Epub]     CrossRef
• New and Future Parenteral Therapies for the Management of Lipid Disorders
  Roberto Garcia, Jaime Burkle
  Archives of Medical Research.2018; 49(8): 538.     CrossRef
• NEW DRUGS FOR THE TREATMENT OF DYSLIPIDEMIA
  Aleksandra Novaković, Marija Marinko, Ivan Stojanović, Dragoslav Nenezić, Predrag Milojević, Vladimir Kanjuh
  Acta Medica Medianae.2018; 57(1): 54.     CrossRef
• Effects of diethylene glycol dibenzoate and Bisphenol A on the lipid metabolism of Danio rerio
  Stefania Santangeli, Valentina Notarstefano, Francesca Maradonna, Elisabetta Giorgini, Giorgia Gioacchini, Isabel Forner-Piquer, Hamid R. Habibi, Oliana Carnevali
  Science of The Total Environment.2018; 636: 641.     CrossRef
• Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment
  Victoria A Serhiyenko, Alexandr A Serhiyenko
  World Journal of Diabetes.2018; 9(1): 1.     CrossRef
• Krüppel-like factor 14, a coronary artery disease associated transcription factor, inhibits endothelial inflammation via NF-κB signaling pathway
  Wenting Hu, Haocheng Lu, Jifeng Zhang, Yanbo Fan, Ziyi Chang, Wenying Liang, Huilun Wang, Tianqing Zhu, Minerva T. Garcia-Barrio, Daoquan Peng, Y. Eugene Chen, Yanhong Guo
  Atherosclerosis.2018; 278: 39.     CrossRef
• Strategies for the use of nonstatin therapies
  Angela Pirillo, Giuseppe D. Norata, Alberico L. Catapano
  Current Opinion in Lipidology.2017; 28(6): 458.     CrossRef
• The efficacy advantage of evolocumab (AMG 145) dosed at 140 mg every 2 weeks versus 420 mg every 4 weeks in patients with hypercholesterolemia: Evidence from a meta-analysis
  Xiao-Xiao He, Rong Zhang, Pei-Yuan Zuo, Yu-Wei Liu, Xiang-Nan Zha, Sheng-Shuai Shan, Cheng-Yun Liu
  European Journal of Internal Medicine.2017; 38: 52.     CrossRef
• The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease
  Carlota Recio, Francesco Maione, Asif J. Iqbal, Nicola Mascolo, Vincenzo De Feo
  Frontiers in Pharmacology.2017;[Epub]     CrossRef
• Emerging biologic therapies for hypercholesterolaemia
  Giacomo Pucci, Arrigo F Cicero, Claudio Borghi, Giuseppe Schillaci
  Expert Opinion on Biological Therapy.2017; 17(9): 1077.     CrossRef
• ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic–therapeutic pathway in Italy
  Michele Massimo Gulizia, Furio Colivicchi, Gualtiero Ricciardi, Simona Giampaoli, Aldo Pietro Maggioni, Maurizio Averna, Maria Stella Graziani, Ferruccio Ceriotti, Alessandro Mugelli, Francesco Rossi, Gerardo Medea, Damiano Parretti, Maurizio Giuseppe Abr
  European Heart Journal Supplements.2017; 19(suppl_D): D3.     CrossRef
• Rev-erb regulation of cholesterologenesis
  Sadichha Sitaula, Jinsong Zhang, Fernanda Ruiz, Thomas P. Burris
  Biochemical Pharmacology.2017; 131: 68.     CrossRef
• Novel lipid modifying drugs to lower LDL cholesterol
  Arjen J. Cupido, Laurens F. Reeskamp, John J.P. Kastelein
  Current Opinion in Lipidology.2017; 28(4): 367.     CrossRef
• 2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document
  Massimo Volpe, Roberto Volpe, Giovanna Gallo, Vivianne Presta, Giuliano Tocci, Emanuela Folco, Andrea Peracino, Elena Tremoli, Bruno Trimarco
  High Blood Pressure & Cardiovascular Prevention.2017; 24(3): 313.     CrossRef
• Sobetirome: the past, present and questions about the future
  Jan Lammel Lindemann, Paul Webb
  Expert Opinion on Therapeutic Targets.2016; 20(2): 145.     CrossRef
• Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes
  Maritza J. Romero, Rudolf Lucas, Huijuan Dou, Supriya Sridhar, Istvan Czikora, Eby M. Mosieri, Ferenc G. Rick, Norman L. Block, Subbaramiah Sridhar, David Fulton, Neal L. Weintraub, Zsolt Bagi, Andrew V. Schally
  Proceedings of the National Academy of Sciences.2016; 113(7): 1895.     CrossRef
• Recent trends in and new data on the epidemiology and prevention of non-communicable diseases
  S. A. Boytsov
  Terapevticheskii arkhiv.2016; 88(1): 4.     CrossRef
• Cellular Model of Atherogenesis Based on Pluripotent Vascular Wall Pericytes
  Ekaterina A. Ivanova, Alexander N. Orekhov, Agnes L. Nishimura
  Stem Cells International.2016;[Epub]     CrossRef
• Pre-treatment with simvastatin prevents the induction of diet-induced atherosclerosis in a rabbit model
  Nikolaos Oikonomidis, Nikolaos Kavantzas, Laskarina-Maria Korou, Panagiotis Konstantopoulos, Vasilios Pergialiotis, Evangelos Misiakos, Ioannis Rizos, Christos Verikokos, Despina N. Perrea
  Biomedical Reports.2016; 5(6): 667.     CrossRef
• Prevention of oxLDL uptake leads to decreased atherosclerosis in hematopoietic NPC1-deficient Ldlr−/− mice
  Mike L.J. Jeurissen, Sofie M.A. Walenbergh, Tom Houben, Marion J.J. Gijbels, Jieyi Li, Tim Hendrikx, Yvonne Oligschlaeger, Patrick J. van Gorp, Christoph J. Binder, Marjo M.P.C. Donners, Ronit Shiri-Sverdlov
  Atherosclerosis.2016; 255: 59.     CrossRef